Poseida Income Quality from 2010 to 2025

PSTX Stock  USD 9.50  0.08  0.84%   
Poseida Therapeutics Income Quality yearly trend continues to be fairly stable with very little volatility. Income Quality is likely to outpace its year average in 2025. Income Quality is an assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure. View All Fundamentals
 
Income Quality  
First Reported
2010-12-31
Previous Quarter
0.86
Current Value
1.07
Quarterly Volatility
0.70582001
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Poseida Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Poseida Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 10.5 M, Income Tax Expense of 101.1 K or Tax Provision of 129.2 K, as well as many indicators such as Price To Sales Ratio of 5.12, Dividend Yield of 0.0 or PTB Ratio of 4.84. Poseida financial statements analysis is a perfect complement when working with Poseida Therapeutics Valuation or Volatility modules.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Latest Poseida Therapeutics' Income Quality Growth Pattern

Below is the plot of the Income Quality of Poseida Therapeutics over the last few years. It is an assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure. Poseida Therapeutics' Income Quality historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Poseida Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Income Quality10 Years Trend
Slightly volatile
   Income Quality   
       Timeline  

Poseida Income Quality Regression Statistics

Arithmetic Mean1.43
Geometric Mean1.25
Coefficient Of Variation49.48
Mean Deviation0.66
Median1.15
Standard Deviation0.71
Sample Variance0.50
Range1.7649
R-Value(0.86)
Mean Square Error0.14
R-Squared0.73
Significance0.000023
Slope(0.13)
Total Sum of Squares7.47

Poseida Income Quality History

2025 1.07
2023 0.75
2022 0.42
2021 0.82
2020 0.87
2019 0.74
2018 0.86

About Poseida Therapeutics Financial Statements

Poseida Therapeutics investors use historical fundamental indicators, such as Poseida Therapeutics' Income Quality, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Poseida Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Income Quality 0.86  1.07 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Poseida Stock Analysis

When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.